On March 31, 2026, Dr. Xuefeng Yu, Chairman and Chief Executive Officer of CanSino Biologics Inc. ("CanSinoBIO"), was featured in an exclusive live interview on Bloomberg TV’s Bloomberg: The China Show. During the interview, Dr. Yu shared insights into the Company’s 2025 performance, its innovation-driven R&D system, and global expansion strategy, outlining CanSinoBIO's development path and long-term strategic vision amid ongoing industry transformation.
Solid Performance Underpins Growth, Operational Quality Improves
According to the Company's 2025 annual results, CanSinoBIO reported total revenue of RMB 1,068 million, representing a year-on-year increase of 26.18%. Net profit attributable to shareholders reached RMB 27.87 million, marking a return to profitability.
Against a backdrop of industry-wide pressure and intensifying competition, the Company has remained committed to its strategy of "innovation-driven growth with a focus on commercialization," optimizing both revenue structure and cost efficiency. As a result, operational quality has improved significantly, laying a solid foundation for sustainable mid- to long-term growth.
Dr. Yu noted that the vaccine industry is undergoing a transition from scale-driven expansion to high-quality development, with competitiveness increasingly defined by the synergy between innovation capabilities and commercialization execution.
Innovation-Driven Pipeline Strength Builds Long-Term Growth Engine
In R&D, CanSinoBIO continues to strengthen its technology capabilities, building a diversified pipeline covering multiple disease areas and forming a well-structured, continuously evolving innovation system.
Among its flagship products, Menhycia® (MCV4), Asia's first quadrivalent meningococcal conjugate vaccine, has demonstrated strong market performance. Its approved age indication has been expanded to children aged 3 months to 6 years, further reinforcing the Company's leadership in meningococcal vaccines. Clinical studies for the 7–59 age group have been completed, unlocking additional commercial potential. The product has also been approved in Indonesia and obtained Halal certification, marking a key milestone in the Company's international expansion.
In the pneumococcal vaccine portfolio, iPneucia® (PCV13i) has been successfully commercialized, while the 24-valent pneumococcal polysaccharide conjugate vaccine 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (PCV24) has commenced clinical development, demonstrating strong iterative R&D capabilities.
Furthermore, the absorbed diphtheria, tetanus, and acellular pertussis (components) combined vaccine (the "DTcP") has been granted priority review, while the adolescent and adult Tdcp vaccine has completed Phase III clinical trials, positioning the Company to achieve full lifecycle coverage from infancy to adulthood.
In addition, the adsorbed tetanus vaccine has entered the New Drug Application (NDA) stage. Innovative programs such as the inhaled tuberculosis vaccine (adenovirus type 5 vector) and the DTcP-Hib-MCV4 combined vaccine are progressing steadily, further strengthening the Company's technology platform. Overseas, CanSinoBIO is collaborating with partners in Malaysia to advance the development of an mRNA-based multivalent influenza vaccine, exploring the global application of next-generation vaccine technologies.
Accelerating Globalization: From Product Export to System-Level Expansion
CanSinoBIO is advancing its globalization strategy from "product export" to "system-level globalization," building integrated capabilities across registration, clinical development, and localized manufacturing.
Focusing on emerging markets in Southeast Asia, the Middle East, and North Africa, the Company is accelerating market access and commercialization. Menhycia® has been launched in Indonesia with supply underway, while further efforts are being made to expand its eligible population. In the Middle East, the Company has entered into vaccine collaboration agreements with partners in Saudi Arabia, exploring joint R&D and localized production models.
Meanwhile, manufacturing facilities for Menhycia® and iPneucia® have received PIC/S GMP certification in Malaysia, providing critical support for global expansion. The inhaled tuberculosis vaccine (adenovirus type 5 vector) has also been approved for clinical trials in Indonesia, further validating the international recognition and scalability of the Company's technology platforms.
Expanding Lifecycle Coverage to Address Evolving Public Health Needs
China's 15th Five-Year Plan emphasizes strengthening public health capacity, enhancing the integration of prevention and treatment, and dynamically optimizing the national immunization program.
Dr. Yu noted that ongoing policy support is reinforcing the public health system and creating new growth opportunities for the industry. As the sector shifts from scale-driven expansion to value-driven growth, CanSinoBIO will continue to enhance its full-lifecycle vaccine portfolio, providing differentiated and innovative solutions to meet increasingly complex public health needs.
Looking Ahead: Towards a Globally Competitive Vaccine Company
Dr. Yu emphasized that the Company's globalization strategy is progressing steadily as planned. Looking ahead, CanSinoBIO will continue to pursue innovation and globalization in parallel, strengthening synergies across R&D, manufacturing, and commercialization while reinforcing its technology platforms and pipeline advantages.
Guided by global public health needs, the Company will accelerate international partnerships and localized operations, delivering innovative, high-quality, and affordable vaccines worldwide, and steadily building a globally competitive vaccine enterprise.
Full Interview Link:
Disclaimer:
Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.
津公网安备12011602300399
